Literature DB >> 12382191

Molecular and genetic markers in the local-regional management of breast cancer.

Bruce G Haffty1.   

Abstract

The clinical application of molecular markers in the diagnosis, staging, and management of breast cancer continues to expand. Although the use of molecular markers in local-regional disease does not approach the level of their application in the systemic management of breast cancer, a growing body of rature supports the potential for molecular and genetic factors in clinical decision making regarding the local-regional management of breast cancer. As with conventional clinical and histopathologic factors, data regarding molecular and genetic factors as they relate to local-regional relapse may be conflicting and are subject to the usual limitations of predominantly retrospective studies. There are, however, some consistent data suggesting associations between local-regional control of disease and several molecular markers, including hormone receptor status, HER2/neu, p53, proliferative markers, and others. Interpretation of these data and how to use this information in clinical practice remains challenging. The available rature regarding the use of genetic and molecular markers in the local-regional management of breast cancer is summarized in this review. Copyright 2002, Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12382191     DOI: 10.1053/srao.2002.35252

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  5 in total

Review 1.  Molecular Subtypes and Local-Regional Control of Breast Cancer.

Authors:  Simona Maria Fragomeni; Andrew Sciallis; Jacqueline S Jeruss
Journal:  Surg Oncol Clin N Am       Date:  2018-01       Impact factor: 3.495

2.  Racial differences in the incidence of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African American compared to white women.

Authors:  B G Haffty; A Silber; E Matloff; J Chung; D Lannin
Journal:  J Med Genet       Date:  2005-06-27       Impact factor: 6.318

3.  Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS + RT).

Authors:  Hasan H Danish; Sharad Goyal; Neil K Taunk; Hao Wu; Meena S Moran; Bruce G Haffty
Journal:  Breast J       Date:  2013-03-26       Impact factor: 2.431

4.  The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.

Authors:  Nikhil G Thaker; Karen E Hoffman; Michael C Stauder; Simona F Shaitelman; Eric A Strom; Welela Tereffe; Benjamin D Smith; George H Perkins; Lei Huo; Mark F Munsell; Lajos Pusztai; Thomas A Buchholz; Wendy A Woodward
Journal:  Springerplus       Date:  2015-01-30

5.  Selective Radiation Therapy for Ductal Carcinoma In Situ Following Breast-Conserving Surgery According to Age and Margin Width: Korean Radiation Oncology Group 11-04 and 16-02 Studies.

Authors:  Kyubo Kim; Jin Hee Kim; Yong Bae Kim; Chang-Ok Suh; Kyung Hwan Shin; Jin Ho Kim; Tae Hyun Kim; So-Youn Jung; Doo Ho Choi; Won Park; Seung Do Ahn; Su Ssan Kim; Ji Woon Yea; Min Kyu Kang; Dong Won Kim; Yi-Jun Kim
Journal:  J Breast Cancer       Date:  2017-12-19       Impact factor: 3.588

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.